Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non- steroidal anti-in ammatory drugs: population based study. BMJ 2005; 330:1370. 244. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298:2634 43. 245. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular dia- stolic lling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981 6. 246. Packer M, O Connor CM, Ghali JK, et al., Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107 14. 247. Levy D, Larson MG, Vasan RS, et al. The progression from hyperten- sion to congestive heart failure. JAMA 1996;275:1557 62. 248. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777 81. 249. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-de brillator for congestive heart failure. N Engl J Med 2005;352:225 37. 250. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845 53. 251. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable de brillator in advanced chronic heart failure. N Engl J Med 2004;350:2140 50. 252. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539 49. 253. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329 38. 254. 